TRex Bio IPO: offering terms from its S-1
TRex Bio priced its IPO at $14 a share on 9 Oct 2026 and raised $117 million. Its shares trade on Nasdaq as TRXB.
Headlines
- Net loss, 2025
- $35M
- IPO price
- $14
- $117M raised
TRex Bio IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- TRXB
- IPO price
- $14
- Shares offered
- 8,333,334
- Raised
- $117M
- Registered
- $153M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, Evercore ISI, Cantor, Stifel, Wedbush and PacGrow
- First filed
- 18 Sep 2026
TRex Bio revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $39M | - | -$3M |
| 2025 | - | -$38M | -$35M |
| First half of 2026 | - | -$31M | -$29M |
TRex Bio share structure and company facts
- Employees
- 60
- Headquarters
- South San Francisco, CA
TRex Bio shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $14
- Priced 9 Oct 2026
- First close
- $14.00
- 0% on the IPO price
- Latest close
- $13.87
- -1% on the IPO price
TRex Bio's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from TRex Bio's newest prospectus (424B4 filed 9 Oct 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.